Literature DB >> 17940880

Percutaneous exposure to VX: clinical signs, effects on brain acetylcholine levels and EEG.

Marloes J A Joosen1, Marcel J van der Schans, Herman P M van Helden.   

Abstract

The nerve agent VX has a variable and delayed absorption through the skin, which may have implications for treatment regimens. In the present study, central and peripheral effects of percutaneous VX intoxication were investigated in hairless guinea pigs. Although onset times of clinical signs varied considerably, the relative onset times of signs of poisoning were shown to have a predictive value for survival time. All animals showed elevation of brain choline (Ch) levels. Only two of six animals demonstrated seizure activity on EEG, which was accompanied by acetylcholine (ACh) accumulation. The non-seizing animals displayed only marginal increases of ACh levels, but significant changes in all EEG bands. Acetylcholinesterase activity was highly inhibited in brain and diaphragm. The increases in Ch levels and EEG effects observed in non-seizing animals probably reflected those of ischemia induced by peripheral effects leading to cardiorespiratory compromise. In conclusion, clinical signs will mainly serve as indicators for the onset and maintenance of treatment in subsequent studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17940880     DOI: 10.1007/s11064-007-9508-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  35 in total

1.  Effects of middle cerebral artery occlusion on cerebral cortex choline and acetylcholine in rats.

Authors:  O U Scremin; D J Jenden
Journal:  Stroke       Date:  1989-11       Impact factor: 7.914

2.  Absorption of the nerve agent VX (O-ethyl-S-[2(di-isopropylamino)ethyl] methyl phosphonothioate) through pig, human and guinea pig skin in vitro.

Authors:  Christopher H Dalton; Ian J Hattersley; Stephen J Rutter; Robert P Chilcott
Journal:  Toxicol In Vitro       Date:  2006-07-08       Impact factor: 3.500

3.  The development of spectral EEG changes during short periods of circulatory arrest.

Authors:  G H Visser; G H Wieneke; A C Van Huffelen; J W De Vries; P F Bakker
Journal:  J Clin Neurophysiol       Date:  2001-03       Impact factor: 2.177

4.  Focal ischemia enhances choline output and decreases acetylcholine output from rat cerebral cortex.

Authors:  O U Scremin; D J Jenden
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

5.  Efficacy of biperiden and atropine as anticonvulsant treatment for organophosphorus nerve agent intoxication.

Authors:  T M Shih; J H McDonough
Journal:  Arch Toxicol       Date:  2000-05       Impact factor: 5.153

6.  Measurement of acetylcholine release in freely moving rats by means of automated intracerebral dialysis.

Authors:  G Damsma; B H Westerink; J B de Vries; C J Van den Berg; A S Horn
Journal:  J Neurochem       Date:  1987-05       Impact factor: 5.372

7.  Acetylcholine and choline dynamics provide early and late markers of traumatic brain injury.

Authors:  Oscar U Scremin; Mingen Grace Li; Margareth Roch; Ruth Booth; Donald J Jenden
Journal:  Brain Res       Date:  2006-11-03       Impact factor: 3.252

8.  Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin.

Authors:  Tjerk J H Bueters; Marloes J A Joosen; Herman P M van Helden; Ad P Ijzerman; Meindert Danhof
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

9.  Function-specific blockage of M(1) and M(3) muscarinic acetylcholine receptors by VX and echothiophate.

Authors:  Zipora Pittel; Dov Barak; Yoffi Segall
Journal:  Brain Res       Date:  2006-04-03       Impact factor: 3.252

10.  Cardiorespiratory effects of O-isobutyl S-[2-(diethylamino)-ethyl] methylphosphonothioate -- a structural isomer of VX.

Authors:  F C Chang; S C Gouty; L C Eder; B E Hoffman; D M Maxwell; K M Brecht
Journal:  J Appl Toxicol       Date:  1998 Sep-Oct       Impact factor: 3.446

View more
  1 in total

1.  Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigs.

Authors:  Helen Mumford; John K Troyer
Journal:  Toxicol Lett       Date:  2011-05-19       Impact factor: 4.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.